Boehringer beats Bayer to the regulators
The FDA will rule on a low dose of zongertinib in the summer.
Innate challenges Pfizer in Nectin-4
While Cogent joins the FGFR party.
Targeted lung cancer niche sees a German pharma battle
But could toxicity be holding back filing plans?
Triple meeting 2024 – can Revolution succeed where others stumbled?
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
World Lung 2024 – Boehringer and Bayer battle over a lung cancer niche
Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.
Boehringer: what’s in and what’s out?
A year-end pipeline update reveals Boehringer Ingelheim’s oncology priorities.
AACR 2024 preview – “cancer vaccines” primed to underwhelm
Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.
